Physician profile
Daniel Alan Rowe
NPI 1902200850
$1,620.66
in general payments reported to CMS, 2019-2025
18 companies · $1,376 in 2025
The $1,376 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $26.98 · 2023: $74.19 · 2024: $143 · 2025: $1,376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,593.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $313.49 | 2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $168.99 | 2025 | |
| Boston Scientific Corporation | $143.12 | 2024 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $139.59 | 2025 | Fasenra, Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $136.26 | 2025 | Dupixent |
| Merck Sharp & Dohme LLC | $95.57 | 2025 | Winrevair |
| Mallinckrodt Hospital Products INC. | $87.13 | 2025 | Acthar |
| Grifols USA, LLC | $79.58 | 2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $76.61 | 2025 | Cuvitru, Glassia |
| Novartis Pharmaceuticals Corporation | $74.19 | 2023 | |
| Inogen, INC. | $60.31 | 2025 | |
| Pulmonx Corporation | $57.40 | 2025 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Verona Pharma, INC. | $45.19 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $44.51 | 2025 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.99 | 2025 | Ofev |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $26.98 | 2022 | |
| Seqirus USA INC | $24.64 | 2025 | Flucelvax, Fluad |
| United Therapeutics Corporation | $18.11 | 2025 | Tyvaso |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.